Erbitux TAILOR-Made For China First-Line mCRC Market, But Brand Recognition Merck’s Real Goal?
This article was originally published in PharmAsia News
Executive Summary
Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux have received a boost with the Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.
You may also be interested in...
Merck KGAA Invests €260m In Production Value Chain in China
German group Merck has inaugurated a major new pharmaceutical plant and announced a further investment in China, where it sees opportunities in essential drugs amid rising demand as the country broadens its basic healthcare coverage and its population ages.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.